In addition, AURKA knockdown improved the sensitivities of PC9 and A549 lung cancer cells to cisplatin in a synergistic manner in cell viability and colony formation assays (CI ˂ 1) (Figure 2C,D). The gene discussed is AURKA; the disease is lung carcinoma.